PHOTOCURE - REPURCHASE PROGRAM OF OWN SHARES

Oslo, Norway, 30 May 2012: Photocure ASA has today
purchased 1400 own shares in the market at an average
price of NOK 38.9061 per share. After this
transaction, Photocure owns a total of 107,460 own
shares.

The transaction is part of share repurchase program,
authorized by the Annual General Meeting held on 27
April 2011 in connection with employee share purchase
program. In accordance with the resolution, the Board
of Directors of Photocure ASA has decided to acquire
up to 250 000 shares. For more details on the
program, please download the minutes from
www.photocure.com (under Investors/Share information).


For further information contact:
Photocure
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email: kh@photocure.no

About Photocure ASA
Photocure ASA is a worldwide leader in photodynamic
technology. Listed on the Oslo Stock Exchange (OSE:
PHO), Photocure is focused on photodynamic
technologies in dermatology and cancer. The company
strives to solve unmet needs by developing new and
innovative solutions based on its patented Photocure
Technology TM. Photocure markets and sells its own
products in selected markets and has developed strong
partnerships with leading pharmaceutical companies on
a regional and global basis. Photocure's bladder
cancer diagnostic product, Hexvix is approved in
Europe and the US. In addition, the company markets
Allumera®, a photodynamic cosmetic in the US. Setting
new standards for diagnosis and treatment of several
different conditions, Photocure Technology TM is
continuously being tested for new products and
applications in cancer and dermatology. Allumera®,
Photocure® and Hexvix® are registered trademarks of
Photocure ASA. For more information about Photocure,
visit www.photocure.com.
This information is subject of the disclosure
requirements acc. to §5-12 vphl (Norwegian Securities
Trading Act).